Aberrant Soluble Epoxide Hydrolase and Oxylipin Levels in a Porcine Arteriovenous Graft Stenosis Model

Christi M. Terry^a Mary L. Carlson^a Yuxia He^a Arzu Ulu^d
Christophe Morisseau^d Donald K. Blumenthal^b Bruce D. Hammock^d
Alfred K. Cheung^{a, c}

^aDivision of Nephrology and Hypertension and ^bDepartment of Pharmacology and Toxicology, University of Utah, and ^cMedical Service, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah, and ^dDepartment of Entomology and Comprehensive Cancer Center, University of California, Davis, Calif., USA

Key Words

Soluble epoxide hydrolase · P450 epoxigenase · Oxylipins · Neointimal hyperplasia · Arteriovenous-graft stenosis

Abstract

Synthetic arteriovenous grafts (AVGs) used for hemodialysis frequently fail due to the development of neointimal hyperplasia (NH) at the vein-graft anastomosis. Inflammation and smooth-muscle cell (SMC) and myofibroblast proliferation and migration likely play an important role in the pathogenesis of NH. Epoxyeicosatrienoic acids (EETs), the products of the catabolism of arachidonic acid by cytochrome P450 enzymes, possess anti-inflammatory, antiproliferative, antimigratory and vasodilatory properties that should reduce NH. The degradation of vasculoprotective EETs is catalyzed by the enzyme, soluble epoxide hydrolase (sEH). sEH upregulation may thus contribute to NH development by the enhanced removal of vasculoprotective EETs. In this study, sEH, cytochrome P450 and EETs were examined after AVG placement in a porcine model to explore their potential roles in AVG stenosis. Increased sEH protein expression, decreased P450 ep-

oxygenase activity and dysregulation of 5 oxylipin mediators were observed in the graft-venous anastomotic tissues when compared to control veins. Pharmacological inhibitors of sEH decreased the growth factor-induced migration of SMCs and fibroblasts, although they had no significant effect on the proliferation of these cells. These results provide insights on epoxide biology in vascular disorders and a rationale for the development of novel pharmacotherapeutic strategies to prevent AVG failure due to NH and stenosis.

© 2014 S. Karger AG, Basel

Introduction

Stenosis with subsequent thrombosis due to underlying neointimal hyperplasia (NH), that forms most often at the vein-graft anastomosis, is the major cause of the failure of synthetic arteriovenous grafts (AVGs) used for chronic hemodialysis [1, 2]. Typically, AVG patency rates are 40% after the first year and decrease to 20% in 3 years [3]. Strategies to prevent NH formation in AVGs are urgently needed.

While many factors contribute to NH development in the AVG, inflammation appears to play a major role because the synthetic graft material is a stimulus to foreign-body inflammatory responses [4, 5]. In addition, the surgical placement of the AVG (1) initiates injury to the barrier and vasculoprotective functions of the luminal endothelial cell layer, (2) activates platelets to release inflammatory and proproliferative proteins, (3) triggers dedifferentiation of smooth-muscle cells (SMCs) to become proliferative and migratory and (4) upregulates transforming growth factor- β expression that promotes the transition of adventitial fibroblasts into proliferative and secretory myofibroblasts that deposit extracellular matrix [4, 6–10]. The shunting of arterial blood directly into the venous circulation also results in highly disturbed blood flow patterns at the vein-graft anastomosis; this likely induces inflammation and cell proliferation [11].

Vasoactive arachidonic acid metabolites include the prostanoids produced by cyclooxygenases, the leukotriene and lipoxins generated by the lipoxygenases and the epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 epoxygenases. Oxidative fatty acid metabolites from polyunsaturated fatty acids, such as linoleic and eicosapentaenoic acid, have been implicated in vascular homeostasis, and cytochrome P450 enzymes also produce hydroxylated metabolites, such as 20-hydroxyeicosatetraenoic acid (20-HETE), that possess generally proinflammatory and prohypertensive properties. Such oxylipids may also be involved in AVG dysfunction, but little is known about their roles in this pathology.

EETs, produced by cytochrome P450 2C and 2J epoxygenases [12], perform potent biological activities including the induction of vasodilation, the inhibition of inflammation, angiogenesis and cell adhesion, proliferation and migration and the inhibition of endothelial cell apoptosis [13–16]. In some cells, EETs inhibit the responses induced by many proinflammatory signaling cascades by blocking the activation of I κ B kinase, inhibiting the activation and nuclear translocation of the transcriptional regulator nuclear factor κ B [14, 17–19]. EETs also can inhibit the activation of the inflammation-responsive c-Jun-N-terminal kinase [20, 21]. They attenuate the expression of some cellular adhesion molecules and decrease the aggregation of platelets and polymorphonuclear cells [22–25]. Another beneficial vascular action of EETs is the promotion of endothelial cell proliferation by the activation of p38 mitogen-activated protein kinase and the prosurvival phosphatidyl-

inositol 3-kinase/Akt pathways [26, 27]. EETs thus play an essential role in maintaining vascular structure and functions.

The bioavailability of EETs is primarily regulated by soluble epoxide hydrolase (sEH) [28]. This enzyme is widely distributed in mammalian tissues. It is responsible for the catabolism of the regioisomeric 5,6-EET, 8,9-EET, 11,12-EET and 14,15-EET lipid mediators into dihydroxyeicosatrienoic acids (DHETs) which are biologically less active than EETs [29]. The 11,12-isomers and 14,15-isomers are the more prevalent regioisomers in the vasculature and the 14,15-isomer is the preferred substrate for sEH [13, 30]. The sEH enzyme plays a role in vascular remodeling in injury-induced vascular stenosis. For example, it was found that pharmacological inhibition of sEH or sEH gene knockout decreased neointimal/medial ratios in a carotid ligation model and in a femoral-cuff injury model in hyperlipidemic mice [31, 32]. Pharmacological inhibitors of sEH have been reported to attenuate end organ damage as well as endothelial dysfunction and inflammation in animal models of cardiovascular diseases such as hypertension, ischemia and hypertrophy [33–38]. Recently, inverse correlations between plasma EET/DHET ratios and both plasma monocyte chemotactic protein-1 and cellular adhesion molecule levels were observed in patients with coronary artery disease [39]. Inasmuch as a lower EET/DHET ratio is a reflection of elevated sEH activity, this observation suggests that elevated sEH activity has a part in the pathogenesis of vascular diseases in humans.

Very recently, an inhibitor of sEH was shown to attenuate cytokine release from human monocyte/macrophages [40]. These intriguing and promising data support the further investigation of oxylipids and sEH in AVG dysfunction.

We hypothesized that sEH is overexpressed in the juxta-anastomotic region of the AVG with a subsequent reduction in tissue EET levels and their associated vasculoprotective effects. This study, focusing on the vascular tissues around the vein-graft anastomosis of the AVG in a porcine model, determined: (1) the activities of P450 epoxygenase that catalyzes EET production, (2) the expression and activities of sEH that catabolizes EETs, (3) the cell types and location within the vascular wall in which sEH is expressed and (4) the tissue oxylipin profile. This should provide an insight into the potential pathogenic role of epoxy fatty acid dysregulation in NH development in AVGs and possibly other vascular disorders, and whether there is a rationale for targeting sEH to prevent AVG failure.

Materials and Methods

Animal Model

All animal experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996). The protocol was approved by the Institutional Animal Care and Use Committees of the University of Utah and the Veterans Affairs Salt Lake Healthcare System.

A porcine AVG model was used in which NH develops at the vein-graft anastomosis consistently around 4 weeks after AVG placement [41, 42]. This location of NH is similar to that commonly observed in patients [43]. Yorkshire cross-domestic swine, aged 3 months and weighing approximately 30 kg, underwent surgical placement of unilateral AVG according to our previously published procedure [44]. Postoperatively, graft patency was monitored weekly using Doppler ultrasound (SonoSite, Bothell, Wash., USA) and an L38/10–5 MHz transducer (TITAN, SonoSite).

Surgical Procedures

For the surgical implantation of the AVG, oral aspirin EC (81 mg/day; Pharmaceutical Formulations, Edison, N.J., USA) and clopidogrel (225 mg/day; Bristol-Myers Squibb, New York, N.Y., USA) were administered perioperatively. Enrofloxacin (5 mg/kg; Bayer, Pittsburgh, Pa., USA) was administered intramuscularly on the day of surgery and daily for the next 3 days. The animals underwent tracheal intubation after anesthetization with an intramuscular injection of xylazine (4 mg/kg), tiletamine/zolazepam (4 mg/kg; Telazol®, Fort Dodge Animal Health, Fort Dodge, Ia., USA) and ketamine (4 mg/kg; Hospira Inc., Lake Forrest, Ill., USA). Anesthesia was maintained with inhalation of 1–3% isoflurane. Intravenous sodium heparin (100 units/kg; Baxter, Deerfield, Ill., USA) was administered intraoperatively. A 7-cm-long, externally spiral-reinforced expanded polytetrafluoroethylene graft (Bard Peripheral Vascular Inc., Tempe, Ariz., USA) with a 6-mm internal diameter was placed between the common carotid artery and the ipsilateral external jugular vein.

Graft and Tissue Explantation and Processing

Juxta-anastomotic venous tissues were obtained at various time points, i.e. at 1 day, 3 days, 1 week, 3 weeks or 4 weeks, as previously described [44]. For immunohistochemistry, tissue sections were fixed in formalin. For all other assays, the explanted vessels were flash-frozen in liquid nitrogen. The tissues were used for histology (n = 13), immunoblotting (n = 5), sEH and P450 epoxide activity assays and oxylipin profiling (n = 4).

Immunoblotting Analysis of Tissue and Cell Lysates

Frozen juxta-anastomotic venous segments explanted 1 (n = 1) or 3 weeks (n = 2) after graft placement were lysed in buffer containing Complete Mini protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) and protein concentrations determined by the bicinchoninic acid assay (Pierce, Rockford, Ill., USA). Twenty-five micrograms of the vessel lysates were separated on 4–12% NuPAGE® Bis-Tris polyacrylamide gels and transferred to nitrocellulose membranes (Invitrogen, Carlsbad, Calif., USA). The membranes were incubated in 5% dry-milk blocking buffer, and then overnight at 4°C with a 1:2,500 dilution of polyclonal rabbit anti-porcine-sEH antibody [45] and a 1:10,000 dilution of monoclonal rabbit-anti-human GAPDH (Cell Signaling, Danvers, Mass., USA). Ten micrograms of lysate from porcine or human

cultured SMCs or murine liver were subjected to SDS-PAGE on 10% gels and transferred to nitrocellulose membranes that were incubated with a 1:200 dilution of rabbit anti-human CYP2J2 (Santa Cruz Biotechnology, Santa Cruz, Calif., USA), or a 1:1,000 dilution of rabbit anti-human sEH (Santa Cruz Biotechnology). For the peptide blocking experiment, anti-sEH antibody was pre-incubated with sEH-specific blocking peptide (Santa Cruz Biotechnology) prior to immunoblotting. The membranes were washed in Tris-buffered saline/Tween solution (TBST) and incubated with a secondary goat anti-rabbit IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology). Supersignal® West Dura extended duration substrate kit (Thermo Scientific, Rockford, Ill., USA) was used for chemiluminescent antibody detection on autoradiography film. Densitometry of each band of interest (sEH or GAPDH) was quantified using the Kodak molecular imaging software v 4.5.1 (Molecular Imaging Systems, Carestream Health, Inc., Rochester, N.Y., USA).

Immunohistochemistry Analysis

Formalin-fixed and paraffin-embedded tissues were deparaffinized and rehydrated using non-xylene Aqua DePar and Hot Rinse ancillary reagents (Biocare Medical, LLC, Concord, Calif., USA). Antigen retrieval was performed using 10 mM sodium citrate in an EZ-Retriever System (BioGenex Laboratories Inc., San Ramon, Calif., USA). Nonspecific binding was blocked with 2% goat serum and the tissue was incubated overnight at 4°C with a rabbit anti-porcine sEH antibody (1:200) [45] and an antibody directed against a murine monoclonal anti- α -smooth muscle actin (α -SMA) conjugated to phycoerythrin (R&D Systems, Minneapolis, Minn., USA) or a murine monoclonal anti-smooth muscle myosin heavy chain (SMMHC, Chemicon Int. Inc., Temecula, Calif., USA) at dilutions of 1:100 and 1:150, respectively. Following an overnight incubation and serial washes in TBST, the tissue sections were incubated for 1 h with an anti-rabbit IgG secondary antibody (Alexa Fluor 488 at 1:200 dilution, Invitrogen) for the detection of sEH, and murine biotin-streptavidin 546 (at 1:200 dilution, Invitrogen) for the detection of SMMHC. After further washing with TBST, a nuclear stain (DAPI-Fluoromount-G, Southern Biotech, Birmingham, Ala., USA) was added.

The slides were analyzed using confocal microscopy (BX61, Olympus America Inc., Center Valley, Pa., USA) at $\times 200$ magnification and excitation wavelengths appropriate for the fluorophores used (405, 488 or 543 nm). Photomultiplier settings were determined using secondary antibodies alone as negative controls. Ten 1.5- μ m slices were generated using the Fluoview FV1000 software (Olympus). The expression of the protein was semiquantified by determining the pixel intensity in z-stacked images imported into Image J (NIH). The number of DAPI-stained nuclei for each Z-stacked image was also determined and used to calculate the amount of sEH expressed per cell. The sEH expression per cell from two replicate histology sections was averaged for the tissue sample from each animal.

P450 Epoxide Activity and sEH Activities

Explanted venous tissues were flash frozen at either 3 (n = 3) or 6 weeks (n = 1) after graft placement for metabolomic analysis. For the analysis of P450 epoxide activity, samples were thawed and maintained in sodium phosphate buffer with 5 mM EDTA, 1 mM PMSF and 1 mM DTT at 4°C [46]. After homogenization and centrifugation at 10,000 g for 10 min at 4°C, the supernatant

was subjected to protein assay and activity measurements. For ep-oxygenase activity assessment, arachidonic acid (100 μ M) was added to diluted sample extracts and incubated at 37°C. After 5 min, 5 μ l of NADPH-generating-system solution (100 mM glucose-6-phosphate, 6 mM NADP⁺, 6 U/ml glucose-6-phosphate dehydrogenase in 0.1 M phosphate buffer, pH 7.4) was added and incubated for 30 min. Ethanol was then added to the reaction with internal EET standards, vortexed and then centrifuged at 2,500 g at 4°C for 4 min. The supernatants were then assayed by LC/MS/MS for the various EET moieties.

For sEH activities, harvested cells were suspended in 1 ml of chilled sodium phosphate buffer (0.1 M, pH 7.4) containing 1 mM of EDTA, PMSF and DTT. The cells were disrupted using a Polytron homogenizer (9,000 rpm for 30 s). The homogenate was used as enzyme extract. Protein concentration was quantified using the bicinchoninic acid assay (Pierce), with Fraction V bovine serum albumin as the calibrating standard. Epoxide hydrolase activity was measured using racemic [³H]-*trans*-1,3-diphenylpropene oxide (tDPPO) as a substrate [47]. Briefly, 1 μ l of a 5-mM solution of [³H]-tDPPO in dimethylformamide was added to 100 μ l of enzyme preparation in sodium phosphate buffer (0.1 M, pH 7.4) containing 0.1 mg/ml bovine serum albumin (final concentration: 50 μ M). The enzyme was incubated at 30°C for 30 min, and the reaction was quenched by the addition of 60 μ l of methanol and 200 μ l of iso-octane, which extracts the remaining epoxide from the aqueous phase. Extractions with 1-hexanol were performed in parallel to assess the possible presence of glutathione transferase activity which could also transform the substrate. The activity was followed by measuring the quantity of radioactive diol formed in the aqueous phase using a scintillation counter (Tri-Carb 2810 TR, Perkin-Elmer, Shelton, Conn., USA) [47]. Assays were performed in triplicate.

Tissue Oxylipin Analysis

Fifty milligrams of porcine anastomotic vein tissues from 3 animals, obtained at 3 weeks after graft placement, or the contralateral unoperated vein tissues were weighed and kept at -20°C for 30 min with 10 μ l of an antioxidant solution (0.2 mg/ml butyl hydroxytoluene and EDTA), 10 μ l internal standard and 400 μ l ice-cold methanol containing 0.1% acetic acid and 0.1% butyl hydroxytoluene. The tissues were homogenized using metal beads in a tissue grinder (Glen Mills Inc., Clifton, N.J., USA) at 30 Hz for 10 min. Resulting homogenates were stored at -20°C overnight and centrifuged at 10,000 g at 4°C for 10 min. The supernatant was collected and the remaining pellets were washed with 100 μ l of ice-cold methanol containing 0.1% acetic acid and 0.1% butyl hydroxytoluene. All collected supernatants were diluted with 2 ml distilled water and the oxylipins were extracted using solid-phase extraction. Once the samples had been passed through a cartridge (Oasis HLB C18 cartridge, Waters Corp., Milford, Mass., USA), the bound oxylipins were eluted using ethyl acetate and samples were evaporated to dryness with a vacuum centrifuge. The samples were then redissolved with 50 μ l of additional standard solution (instrumental standard) in methanol and measured by mass spectrometry [48].

Cell Proliferation and Migration Studies

The compounds *trans*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (tAUCB) and (3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) are selective inhibitors of hu-

man sEH, with 50% inhibition of 1.3 ± 0.1 and 3.0 ± 0.5 nM, respectively (observed in biochemical assays) [49, 50]. SMCs and adventitial fibroblasts were isolated from a normal porcine jugular vein using published techniques [51]. The human aortic SMCs and fibroblasts (Cambrex Bio Science, Chicago, Ill., USA) and the porcine venous SMC and fibroblasts (passages 5–8) were seeded into 96-well tissue culture plates at subconfluence and made quiescent by incubation in media with no serum for 48 h. The cells were pretreated with either dimethylsulfoxide alone or an sEH inhibitor (AUDA or tAUCB) at 0.1–10 μ M in the absence or presence of EETs (11,12-EET or 14,15-EET, Cayman Chemical, Ann Arbor, Mich., USA) for 1 h. Cell proliferation was stimulated with either PDGF-AB (50 ng/ml; R&D Systems) or 10% FBS for 48 h and assessed with a colorimetric assay following the manufacturer's protocol (CellTiter 96 AQueous One, Promega, Madison, Wisc., USA). The wounding assay was used for assessing cell migration and was performed by seeding the cells to subconfluence onto 4-chamber slides (Lab-TekII, Nunc, Rochester, N.Y., USA). Quiescent cells were then wounded by dragging a pipette tip across the middle of each chamber. The chambers were washed and medium containing PDGF-AB (50 ng/ml) was added to each chamber with or without imatinib (10 μ M; Gleevec, Novartis Pharmaceuticals Corp., East Hanover, N.J., USA) or AUDA (10 μ M) and incubated for 24 h. The cells were then fixed in methanol and stained with the Diff-Quick® stain set (Dade Behring, Inc., Newark, Del., USA).

For the migration studies, the human aortic SMCs or human adventitial fibroblasts were serum-starved for 24 h and pretreated with either dimethylsulfoxide or one of the sEH inhibitors, tAUCB or AUDA, at 1 or 5 μ M for 1 h. After pretreatment, the cells were seeded onto the upper well of a migration chamber insert (Inno-Cyte™ 96-well, Calbiochem, La Jolla, Calif., USA) containing a porous 8- μ m membrane separating the upper and lower chambers. Chemotaxis was stimulated by the addition of PDGF-AB (25 ng/ml) to minimal culture medium in the lower chamber of the 96-well migration plate. Cells were incubated at 37°C in a humidified chamber with 5% CO₂ for 15 h and then processed according to the manufacturer's instructions for cell detachment and Calcein-AM labeling. Fluorescence quantification of the migrated cells was determined by a fluorescent plate reader with excitation and emission wavelengths of 485 and 520 nm, respectively.

Statistical Analysis

Values of sEH expression by immunohistofluorescence staining of tissues obtained from juxta-anastomotic venous tissue sections were compared to those obtained from the external jugular veins, i.e. the CVs, using the unpaired Student *t* test. Separate analyses were performed to compare venous anastomotic tissues obtained from the early postoperative period (within 1 week; *n* = 5) to controls and to compare venous anastomotic tissues obtained later (at 3 and 4 weeks; *n* = 4) to the controls. A *p* value <0.05 was considered to be statistically significant.

Analysis of variance (ANOVA) was used to compare the log-transformed tissue levels of 8,9-EETs, 11,12-EETs and 14,15-EETs between the venous anastomotic tissues and the control veins (CVs). The ANOVA model included separate factors for the various EETs and for the comparison between the venous anastomosis and the CV, with the individual animal treated as a blocking factor. This analysis was used to perform a pooled comparison of the log-transformed tissue levels between the venous anastomosis and CV across the 3 substrates (EETs), and to evaluate if these levels differed.

Fig. 1. sEH expression in tissues of the vein-graft anastomosis after AVG placement in the pig. **a** Cartoon depicting the polytetrafluoroethylene (PTFE) graft placed between the common carotid artery and ipsilateral external jugular vein. The rectangular box outlines the approximate vein-graft anastomotic area analyzed for sEH and oxylipins in figures 1–5. **b** Lysates were prepared from the vein-graft anastomotic tissues harvested 1 (n = 1) or 3 weeks (n = 2) after graft placement or from the normal external jugular vein

(CV) of an unoperated pig (n = 2), and analyzed by SDS-PAGE followed by immunoblotting with anti-sEH antibody. Protein loading was assessed by immunostaining with anti-GAPDH antibody. Band intensity from sEH immunostaining was measured and protein loading was corrected by dividing by GAPDH band intensity. The normalized sEH band intensity is displayed in a bar graph.

In exploratory analyses, separate paired t tests were performed to compare log-transformed tissue levels for 32 oxylipins between venous anastomosis and the CV, with results expressed as the ratio of geometric means with 95% confidence intervals (CIs). These exploratory analyses were performed on a comparison-wise basis, without adjustment for multiple comparisons. In addition, an unpaired Student t test was used to evaluate differences in fluorescent intensities between cells migrating in the presence or absence of sEH inhibitors in the migration assay. $p < 0.05$ was considered significant.

Results

Immunoblotting of sEH in the Tissues of the Vein-Graft Anastomosis

As stenotic lesions occur most frequently at the vein-graft anastomosis, lysates were prepared from the anastomotic venous tissues (fig. 1a) from pigs at 1 or 3 weeks after surgical graft placement. Lysates were also obtained from the external jugular veins from unoperated normal

pigs; these served as controls. Levels of sEH protein were determined by immunoblotting. A protein band with an apparent molecular weight of 62 kD was detected with the antiporcine sEH antibody (fig. 1b). Densitometric quantification of these bands showed a 2-fold increase in sEH protein in the vein-graft anastomosis tissue compared to the levels observed in the CVs (fig. 1b).

Immunohistofluorescence of sEH in the Tissues of the Vein-Graft Anastomosis

Immunohistofluorescence was used to confirm the immunoblot finding of elevated sEH expression and to identify the location of the sEH within the vascular wall. The expression of sEH increased in the anastomotic venous tissues early (at 1 week) after graft placement compared to the CVs (fig. 2a). The increased sEH staining was most prominent in the adventitial layer at 1 week, persisting for up to 3 (fig. 2a, b) and 4 weeks (the longest time point examined; data not shown). At 3 weeks, increased sEH expression was also apparent in the medial layer

Fig. 2. Expression of sEH in tissues of the vein-graft anastomosis as determined by immunohistofluorescence and confocal laser scanning microscopy. **a** Immunohistofluorescence images of a normal external jugular vein (the CV) and anastomotic tissues explanted 1 or 3 weeks after AVG placement (sEH staining: green and DAPI nuclear stain: blue). $\times 200$. Scale bars: 50 μm . A = Adventitia; L = lumen; M = media; N = neovessel. **b** Composite semiquantitative data of sEH immunostaining intensity of the CV (n = 4) and the vein-graft tissue collected early, i.e. at day 1 (n = 1), day 3 (n = 1) and after 1 week (n = 3), and then later, i.e. after 3 (n = 2) and 4 weeks (n = 2). After normalization against the cell number, sEH expression at the early time points was significantly higher at the venous anastomosis than that observed in the CV (64.3 ± 7.3 vs. 43.8 ± 16.4 pixel intensity/cell; * p < 0.05). The sEH expression remained elevated at the later time points compared to the CV (84.7 ± 13.0 vs. 43.8 ± 16.4 pixel intensity/cell; ** p < 0.01).

(fig. 2a). Expression of sEH was high in the luminal endothelium of the CV but was decreased in a sporadic fashion in the endothelium at later time points (fig. 2a). The expression of sEH in the entire tissue section was quantified by measuring the pixel intensity of the sEH staining. Even after normalization against the cell number, the increased expression of sEH was apparent within 1 week (early) and remained increased at 3–4 weeks (late) compared to the CVs (fig. 2b).

Immunohistochemical staining with anti-von Willebrand factor antibody revealed some loss of endothelial cells at the anastomotic venous tissues 1 week after AVG placement (data not shown), likely due to surgical trauma. Costaining of sEH and von Willebrand factor was unsuccessful despite repeated attempts. Thus, it could not be determined if the diminished sEH immunostaining in the luminal cells was as a result of decreased sEH expression or the loss of endothelial cells. Numerous small vessels that stained positive for sEH were observed in the adventitia at the later time points.

Types of Cells Expressing sEH in the Tissues of the Vein-Graft Anastomosis

Both differentiated quiescent SMCs of normal venous vessels and dedifferentiated synthetic SMCs express α -SMA. Fibroblasts that have dedifferentiated to the migratory and proliferative myofibroblast phenotype acquire the expression of α -SMA. In contrast to α -SMA, SMMHC is expressed exclusively by differentiated quiescent SMCs. Thus, an increase in α -SMA expression and a decrease in SMMHC expression suggest the dedifferentiation of quiescent contractile SMCs to the proliferative, synthetic SMC phenotype and/or the presence of myofibroblasts. Such cells are associated with NH development. Coimmunostaining experiments were performed to examine the colocalization of sEH expression with α -SMA and SMMHC expression in the vessel wall. The coexpression of sEH and α -SMA in the CVs was limited in nature and was confined to the medial layer (fig. 3a, 1st row). In contrast, in the anastomotic venous tissues collected at 1 week, the coimmunostaining for sEH and α -SMA was much stronger, in-

Fig. 3. Characterization of cell types at the vein-graft anastomosis as determined by immunohistofluorescence and confocal laser scanning microscopy. **a** Sequential histology sections of the anastomotic tissues, obtained at 1 or 3 weeks, and of CVs, were immunostained with anti-sEH (green in left column), anti- α -SMA (red in middle column) or coimmunostained (right column) with anti-sEH, anti- α -SMA and DAPI nuclear stain (blue). Coexpression of sEH and α -SMA appears yellow, or else orange when the α -SMA expression was slightly higher than sEH expression. α -SMA expression was confined to the medial layer in the CV, with limited coexpression of sEH and α -SMA. In the anastomotic-vein tissue collected at 1 and 4 weeks after graft placement, α -SMA staining was prominent in the adventitia as well as the media. Costaining for sEH and α -SMA was conspicuous in the media at 1 week and

increased in the media and NH at 4 weeks (overlay panels). **b** Sequential histology sections of the anastomotic tissues or CVs were stained with anti-sEH (green in left column) or anti-SMMHC (red in middle column) or coimmunostained (right column) with anti-sEH, anti-SMMHC and DAPI (blue). In contrast to α -SMA, staining for SMMHC was not apparent in the adventitia of AVG tissue, except for at 3 weeks, when SMMHC could be readily observed in or around the neovascular walls (bottom panel of middle column). Costaining of SMMHC with sEH (yellow in the overlay panels) was evident in the media at 1 week, but had mostly disappeared at 3 weeks. In contrast to α -SMA, costaining of SMMHC in the NH region was very low at 3 weeks (overlay panel). A = Adventitia; L = lumen; M = media; NI = neointima; NV = neovessel.

creased over time and occurred in the adventitia (fig. 3a, 2nd and 3rd rows). In contrast, coimmunostaining for sEH and the marker for contractile differentiated SMCs (SMMHC) in the medial layer in the AVG decreased over time compared to in the CV (fig. 3b). These data suggest that an increase in sEH expression in the tissue at the vein-graft anastomosis is associated with dedifferentiation of SMCs to a more synthetic, proliferative and migratory phenotype.

In addition to the medial layer, costaining for sEH and α -SMA was strong in the NH at 1 and 3 weeks (fig. 3a), but costaining for sEH and SMMHC was very low in these regions (fig. 3b), suggesting that the sEH-expressing cells in the NH were dedifferentiated SMCs or myofibroblasts. Numerous neovessels were observed at 3–4 weeks after graft placement (fig. 3a, b).

P450 Epoxygenase and sEH Activities in the Tissues of the Vein-Graft Anastomosis

The levels of 8,9-EET, 11,12-EET and 14,15-EET, the products of tissue P450 epoxygenase activity, were evaluated in tissue obtained from the vein-graft anastomosis and the CV at 3 weeks. The mean P450 epoxygenase activity to produce all 3 EETs combined was 3.1 and 6.4 pmol/min/mg, respectively, in the anastomotic tissues of the 3 animals and the 3 CVs (fig. 4). ANOVA analysis after log-transformation of epoxygenase activity data showed that epoxygenase activities were significantly lower ($p < 0.001$) in the anastomotic tissues than in the CVs for these EET moieties; the ratio of geometric means of anastomosis to control was 0.54 (95% CI 0.42–0.71). No difference was observed for the epoxygenase activities generating 5,6-EET (data not shown), an epoxide that is less prevalent and less stable than the 3 aforementioned

Fig. 4. Epoxygenase and sEH activities in the tissues of the vein-graft anastomosis. CYP2C and CYP2J epoxygenase activities were assessed in venous anastomotic (VA) tissues and CVs. The mean levels of 8,9-EET, 11,12-EET and 14,15-EET were lower in the VA tissues than in the CVs ($p < 0.001$).

Fig. 5. Five oxylin with statistically significantly different levels between tissues of the vein-graft anastomosis and CV tissues. The data are displayed as a forest plot of the ratio of geometric means between venous anastomosis ($n = 3$) and CV ($n = 3$) with 95% CIs. The levels of 9-HODE, 13-HODE and 12,13-DiHOME were decreased, while the levels of PGD₂ and 12-HETE were increased in the anastomotic tissues when compared to the CVs ($p < 0.05$).

Table 1. The ratio of geometric means of oxylin in the tissue of the vein-graft anastomoses (obtained at 3 weeks after AVG placement) to oxylin in the CV tissue

N	Oxylin	AVG:CV ratio	95% CI
1	11-HETE	0.12	0.0–100.6
2	6-keto-PGF _{1α}	0.16	0.02–1.45
3	PGE ₂	0.22	0.01–4.69
4	Resolvin E ₁	0.37	0.07–1.97
5	15-deoxy-PGJ ₂	0.42	0.04–4.16
6	11,12,15-TriHETrE	0.54	0.04–6.74
7	LTB ₄	0.57	0.09–3.65
8	9,10-DiHOME	0.57	0.22–1.5
9	8,9-DHET	0.58	0.17–1.94
10	15(S)-HETrE	0.59	0.20–1.73
11	9-oxo-ODE	0.68	0.08–5.55
12	LXA ₄	0.70	0.28–1.74
13	12,13-EpOME	0.70	0.22–2.27
14	13-oxo-ODE	0.76	0.01–5.86
15	9,10-EpOME	0.79	0.16–3.90
16	TXB ₂	0.81	0.24–2.68
17	11,12-DHET	0.87	0.05–15.62
18	9,10,13-TriHOME	0.87	0.12–6.35
19	15-HETE	0.92	0.08–10.80
20	9,12,13-TriHOME	0.97	0.13–7.30
21	14,15-DHET	0.97	0.27–3.45
22	5-HETE	1.12	0.63–1.99
23	11,12-EET	1.21	0.48–3.04
24	14,15-EET	1.22	0.63–2.39
25	15-oxo-ETE	1.33	0.11–15.57
26	8,9-EET	1.34	0.18–9.74
27	5,6-EET	1.44	0.63–3.31
28	PGF _{2α}	1.59	0.35–7.24

15-deoxy-PGJ₂ = 15-deoxy-prostaglandin J₂; EpOME = epoxyoctadecenoic acid; 6-keto PGF_{1α} = 6-keto-prostaglandin F_{1α}; LTB₄ = leukotriene B₄; LXA₄ = lipoxin A₄; 9-oxo-ODE = oxo-octadecadienoic acid; 15-oxo-ETE = oxo-eicosatetraenoic acid; PGE₂ = prostaglandin E₂; PGF_{2α} = prostaglandin F_{2α}; Resolvin E₁ = trihydroxyeicosapentaenoic acid; 15(S)-HETrE = hydroxyeicosatrienoic acid; TriHETrE = trihydroxyeicosatrienoic acid; TriHOME = trihydroxyoctadecenoic acid; TXB₂ = thromboxane B₂.

EETs. sEH activity was also measured in these tissues, but the results were highly variable amongst animals, and there was no significant difference in mean sEH activity between the venous anastomotic tissues and the CVs (101.0 ± 54.9 and 84.7 ± 70.2 pmol/min/mg) at the 3-week time point. However, venous anastomosis tissue from 1 pig collected 6 weeks after graft placement displayed increased sEH activity compared to the unoperated femoral vein (77.3 vs. 19.5 pmol/min/mg).

Fig. 6. CYP2J2 and sEH expression in SMCs and effect of EETs and/or sEH inhibitor on PDGF-induced proliferation of human SMCs or fibroblasts. **a** Cell lysates from porcine SMCs were size-fractionated, transferred and then immunostained with anti-sEH antibody in the absence (-) or presence (+) of an sEH-specific blocking peptide (left blot). Lysates from murine liver or human SMCs were immunostained with anti-human CYP2J2 antibody which detected a protein of approximately 57 kD (right blot). **b** SMCs were serum-starved and then induced to proliferate with PDGF (50 ng/ml). The addition of EETs (0.1–10 μ M) in the absence or presence of the sEH inhibitor AUDA (0.1 μ M) did not inhibit proliferation. **c** AUDA (0.1–10 μ M) had no significant effect on fibroblast proliferation induced by 10% FBS. Each bar represents the mean $\pm$ SD of 3 or 4 observations.

Oxylipin Levels in the Tissues of the Vein-Graft Anastomosis

A profiling of 38 oxylipin levels was performed on the vein-graft anastomotic tissue of 3 animals 3 weeks after AVG placement and was compared to levels in unoperated CVs. Five of the assayed oxylipins were below the limit of detection. The levels of 28 oxylipins in the CVs and the anastomotic tissues were similar (table 1). However, the vein anastomotic tissues displayed significantly

decreased levels of 3 oxylipins: 9- and 13-hydroxyoctadecadienoic acid (9-HODE and 13-HODE) and 12,13-dihydroxyoctadecadienoic acid (12,13-DiHOME) by 3.0-, 2.1- and 1.5-fold, respectively ($p < 0.05$, ANOVA; fig. 5). In contrast, prostaglandin D₂ (PGD₂) and 12-HETE were found to be significantly increased by 2.0- and 5.7-fold, respectively, in the anastomotic tissues when compared to the CVs ($p < 0.05$; fig. 5).

Fig. 7. Effect of sEH inhibitor (sEHI) AUDA (10 μ M) and EETs on human SMC migration using a wounding assay. AUDA with or without 11,12 EET inhibited the inward migration of cells into the wounded area in response to PDGF treatment similar to that seen with the PDGF receptor inhibitor, imatinib.

Color version available online

Fig. 8. Effect of sEH inhibitors on PDGF-stimulated migration of human SMCs and fibroblasts through a porous membrane. **a** Human aortic SMCs were seeded in the upper chamber of the migration apparatus after pretreatment with 1 of 2 concentrations of either AUDA or tAUCB. Migration is shown as a percent of that seen with PDGF alone without inhibitors. **b** Human adventitial fibroblasts were seeded into the upper chamber after pretreatment with 1 of the 2 inhibitors. * $p < 0.05$ versus PDGF alone.

The Effect of Epoxyeicosatrienoic Acid and sEH Inhibitor on Cell Proliferation and Migration

Immunoblotting of lysates from cultured porcine or human SMCs detected sEH protein (fig. 6a, left blot). The P450 epoxygenase isoform CYP2J2 metabolizes arachidonic acid to EETs, and its expression was detected in cultured SMCs (fig. 6a, right blot). However, neither

11,12-EETs nor the combination of EETs and the sEH inhibitor, AUDA, significantly affected the proliferation of SMCs (fig. 6b). Other EETs and different concentrations of AUDA were tested, but also showed no significant effect (data not shown). Figure 6c shows that AUDA alone had no significant effect on adventitial fibroblast proliferation. Exposure to EETs or AUDA plus EETs did not significantly affect fibroblast proliferation either (data not shown), and exposure to 14,15-EET and/or another pharmacological sEH inhibitor did not attenuate proliferation (data not shown).

The effects of EETs and/or the sEH inhibitor on SMC chemotaxis was determined by both a wounding assay and a Boyden chamber-type assay. Figure 7 shows that AUDA attenuated PDGF-induced human aortic SMC migration across a wound area similar to that observed with imatinib, a PDGF receptor kinase inhibitor. Similarly, two different inhibitors of sEH, i.e. tAUCB and AUDA, attenuated PDGF-induced SMC migration and adventitial fibroblast migration through a porous filter (fig. 8).

Discussion

Cytochrome P450 epoxygenases metabolize arachidonic acid to EETs which have anti-inflammatory, vasodilatory and other vasculoprotective properties, while sEH rapidly catabolizes the EETs. Other studies have reported the efficacy of sEH inhibitors in attenuating atherosclerosis, abdominal aortic aneurysm formation and hypertension-induced NH in various animal models [31–38]. This study addressed the potential role of altered epoxygenase and sEH pathways in the pathogenesis of NH associated with AVG in a large animal model.

The expression of sEH was low in the media and adventitia of the unoperated CV but increased early and remained elevated for several weeks in the tissue of the vein-graft anastomosis region after AVG placement. Increased sEH expression was predominant in the medial SMCs

and cells in the adventitia, concomitant with the appearance of synthetic dedifferentiated SMCs and/or myofibroblasts as determined by the increased expression of α -SMA, a marker of dedifferentiation. Dedifferentiation of SMCs and fibroblasts to a more synthetic phenotype occurs with vascular trauma and results in a greater proliferative and migratory capacity as well as increased synthesis of collagen and other extracellular-matrix proteins [52–54]. We previously reported that adventitial cells become highly proliferative soon after AVG placement in the porcine model, and that these cells, like the medial SMCs, likely contribute to NH by migrating to the neointima [55]. The early onset of and prolonged increase in sEH protein expression in SMCs and adventitial cells is consistent with the notion that elevated sEH expression is important in the development of NH in AVGs.

We found that exogenous EETs and/or pharmacological inhibitors of sEH had little effect on the proliferation of SMCs or fibroblasts. In other studies, EETs alone also failed to influence SMC proliferation [16, 56]. It was previously reported that another sEH inhibitor attenuated SMC proliferation [57], but the inhibitory effect was later shown to actually be unrelated to the sEH inhibition [58]. Ng et al. [59] reported that AUDA and EETs inhibited PDGF-BB-induced proliferation of aortic SMCs. These conflicting results across studies could be due to differences in the source of the SMCs (i.e. aortic vs. venous or pulmonary) and/or isoform of the platelet-derived growth factor (PDGF), i.e. PDGF-BB or PDGF-AB, the PDGF concentration employed and/or the timing of the drug exposure.

In our study, neither SMC nor fibroblast proliferation was inhibited, but SMC migration was significantly attenuated by sEH inhibitors; this is similar to the report by Sun et al. [16]. Previous work by our group has also shown that macrophage accumulation and cytokine expression are pronounced features of AVG stenosis and that a pharmacological inhibitor of sEH caused a significant decrease in release of monocyte-chemotactic protein-1 and TNF from lipopolysaccharide-stimulated human monocytes in vitro [40]. The data presented here, together with previous works, suggest that sEH inhibition could be useful for the prevention of AVG stenosis by targeting both inflammation and cell migration.

Decreased activity of the P450 epoxygenases that produce EETs was observed in the vein-graft anastomosis tissue (fig. 4), suggesting a decrease in the production of EETs compared to in the CV tissue. However, no significant difference in 8,9-EET, 11,12-EET or 14,15-EET levels (table 1) was observed in these same lysates, even

Fig. 9. Proposed cellular arachidonic acid metabolic pathways that contribute to NH formation at vein-graft anastomosis after AVG placement. Moieties that were observed to be decreased in the venous anastomotic tissues compared to CVs (EETs, 12,13-DiHOME, 9-HODE and 13-HODE) are highlighted by black borders, while moieties that were observed to be increased are highlighted by gray borders. Reduced epoxygenase activity and/or increased sEH activity would contribute to the decreased EET levels and also shunt the polyunsaturated fatty acid substrates to the COX and LO pathways. The proinflammatory mediators PGD₂ and 12-HETE were produced by COX1/2 and 12-LO enzymes, respectively. The decreased 9-HODE and 13-HODE levels observed may be the result of decreased oxidation of low-density lipoprotein. AA = Arachidonic acid; EPA = eicosapentaenoic acid; COX1/2 = cyclooxygenase 1 or 2; CYP2C/2J = cytochrome P450 2C or 2J; EpOME = 12,13-epoxyoctadecenoic acid; 6-keto PGF_{1α} = 6-keto-prostaglandin F_{1α}; LA = linoleic acid; 12-LO = 12-lipoxygenase; PGE₂ = prostaglandin E₂; PGH₂ = prostaglandin H₂; PGI₂ = prostacyclin; oxLDL = oxidized low-density lipoprotein; RvE1 = resolvin E1.

though the Western blot and immunohistochemical studies showed an increase in sEH protein levels in the vein-graft tissue. Graft placement triggers drastic changes in blood flow rate and patterns in the vein, and consequently may cause changes in gene expression in the ungrafted contralateral vessels. It is also possible that there were concomitant compensatory decreases in other EET breakdown pathways in the vein-graft tissue. There were significant decreases in 12,13-DiHOME (an isoleukotoxin diol product of the P450 epoxygenase pathway), 9-HODE and 13-HODE (produced during the oxidation of low-density lipoprotein). The 12,13-DiHOME, 9-HODE and 13-HODE are endogenous activating ligands for peroxisome proliferator-activated receptor

(PPAR)- γ [60–62]. The activation of PPAR- γ decreases vascular SMC proliferation and migration [63, 64] and inhibits the activation of macrophages [65, 66]. Decreases in these oxylipin PPAR- γ agonists after AVG placement may thus contribute to prolonged inflammation and potentiate NH formation.

Two proinflammatory eicosanoid mediators, PGD₂ and 12-HETE, were found to be significantly increased at the vein-graft anastomosis. PGD₂ is produced by prostaglandin synthase D₂ and has been shown by in vitro studies to be an SMC mitogen released by human umbilical venous endothelial cells following hypoxia [67]. 12-HETE is produced by 12-lipoxygenase activity and has been implicated in angiogenesis, neutrophil aggregation and vasoconstriction [68–72]. Of note, neovessel formation likely supports NH development by providing nutrients to the growing tissues and allowing access for inflammatory cells. The elevated 12-HETE observed in the vein-graft tissue may thus participate in NH development via promoting neovessel formation.

The various biological activities of the several fatty acid mediators that we found to be dysregulated are consistent with a role for oxylipins in the pathogenesis of NH in the AVG. Regulation of inflammation and NH in the AVG appears to be complex, as a result of changes in multiple lipid mediators, cytokines, chemokines and other factors. These proposed lipid metabolic pathways are illustrated in figure 9. Since both the propagation and resolution of inflammation are critical pathophysiological and physiological processes, therapeutic alteration of these processes can have complex outcomes. Nonetheless, targeting sEH and other related key enzymes may be an effective therapeutic strategy to prevent NH in the AVG.

We acknowledge the following limitations of our study. The porcine model used for this study develops inflammation, NH and graft stenosis similar to that seen in

humans. However, the animals had intact kidney function, and it is possible that impaired kidney function would accelerate such processes and/or alter sEH expression. This work used a costly, labor-intensive, large animal model because AVGs cannot reasonably be placed in small animals. The advantage is that data from this model are likely more translatable to patients because the hemodynamics and foreign-body responses are similar to those in humans. The results of the immunoblotting and IHC experiments are consistent with each other and indicate elevated sEH protein in the vein-graft tissue, and are supported by the elevated sEH activity in 1 animal analyzed at 6 weeks after graft placement. However, there is a risk of false discovery, and caution should be taken in interpreting the oxylipin levels and enzyme activity data due to the small number of animals used in the sEH activity experiments. The antiplatelet drugs clopidogrel and aspirin were administered to all animals before and after graft placement surgery. Aspirin is commonly used in chronic hemodialysis patients. It inhibits the cyclooxygenases in the arachidonic acid pathway and may inhibit the production of EETs by competing for the arachidonate substrate. Clopidogrel has no known effects on arachidonate metabolism.

Acknowledgements

The authors thank Huan Li and Ilya Zhuplatov for performing surgery on the animals. This study was supported by the Veterans Affairs Merit Review Program (A.K.C.). Partial support was provided by the National Institute of Environmental Health Sciences (B.D.H.). The statistics analysis was performed by the University of Utah Study Design and Biostatistics Center under the guidance of Tom Greene, with funding in part from the Public Health Services research grants (No. UL1-RR025764 and No. C06-RR11234) from the National Center for Research Resources. B.D.H. is a George and Judy Marcus Fellow of the American Asthma Foundation.

References

- 1 Feldman HI, Koblin S, Wasserstein A: Hemodialysis vascular access morbidity. *J Am Soc Nephrol* 1996;7:523–535.
- 2 Gibson KD, et al: Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study. *J Vasc Surg* 2001;34:694–700.
- 3 Dixon BS, et al: Effect of dipyridamole plus aspirin on hemodialysis graft patency. *N Engl J Med* 2009;360:2191–2201.
- 4 Ai D, et al: Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. *Proc Natl Acad Sci USA* 2007;104:9018–9023.
- 5 Sanders WG, et al: A biodegradable perivascular wrap for controlled, local and directed drug delivery. *J Control Release* 2012;161:81–89.
- 6 Roy-Chaudhury P, et al: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. *Kidney Int* 2001;59:2325–2334.
- 7 Shi Y, et al: Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. *Circulation* 1996;94:1655–1664.
- 8 Tsai S, et al: TGF-beta through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. *Am J Physiol Heart Circ Physiol* 2009;297:H540–H549.
- 9 Roy-Chaudhury P, Sukhatme VP, Cheung AK: Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. *J Am Soc Nephrol* 2006;17:1112–1127.

- 10 Weiss MF, Scivittaro V, Anderson JM: Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. *Am J Kidney Dis* 2001;37:970–980.
- 11 Honda HM, et al: A complex flow pattern of low shear stress and flow reversal promotes monocyte binding to endothelial cells. *Atherosclerosis* 2001;158:385–390.
- 12 Zeldin DC: Epoxygenase pathways of arachidonic acid metabolism. *J Biol Chem* 2001;276:36059–36062.
- 13 Spector AA, Norris AW: Action of epoxyeicosatrienoic acids on cellular function. *Am J Physiol Cell Physiol* 2007;292:C996–C1012.
- 14 Node K, et al: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. *Science* 1999;285:1276–1279.
- 15 Imig JD: Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. *Cardiovasc Drug Rev* 2006;24:169–188.
- 16 Sun J, et al: Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. *Circ Res* 2002;90:1020–1027.
- 17 Kessler P, et al: Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. *Circulation* 1999;99:1878–1884.
- 18 Node K, et al: Activation of G α s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. *J Biol Chem* 2001;276:15983–15989.
- 19 Spiecker M, Liao JK: Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. *Arch Biochem Biophys* 2005;433:413–420.
- 20 Potente M, et al: Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. *J Biol Chem* 2002;277:15671–15676.
- 21 Skepner JE, et al: Chronic treatment with epoxyeicosatrienoic acids modulates insulin signaling and prevents insulin resistance in hepatocytes. *Prostaglandins Other Lipid Mediat* 2011;94:3–8.
- 22 Falck JR, et al: 11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF- α -induced VCAM-1 expression. *Bioorg Med Chem Lett* 2003;13:4011–4014.
- 23 Krotz F, et al: Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. *Arterioscler Thromb Vasc Biol* 2004;24:595–600.
- 24 Heizer ML, McKinney JS, Ellis EF: 14,15-Epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. *Stroke* 1991;22:1389–1393.
- 25 Pratt PF, Rosolowsky M, Campbell WB: Effects of epoxyeicosatrienoic acids on polymorphonuclear leukocyte function. *Life Sci* 2002;70:2521–2533.
- 26 Fleming I, Busse R: Endothelium-derived epoxyeicosatrienoic acids and vascular function. *Hypertension* 2006;47:629–633.
- 27 Fleming I, et al: The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. *Pflügers Arch* 2001;442:511–518.
- 28 Newman JW, Morisseau C, Hammock BD: Epoxide hydrolases: their roles and interactions with lipid metabolism. *Prog Lipid Res* 2005;44:1–51.
- 29 Daikh BE, et al: Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. *J Pharmacol Exp Ther* 1994;271:1427–1433.
- 30 Yu Z, et al: Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. *Circ Res* 2000;87:992–998.
- 31 Revermann M, et al: Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. *Arterioscler Thromb Vasc Biol* 2010;30:909–914.
- 32 Simpkins AN, et al: Soluble epoxide hydrolase inhibition modulates vascular remodeling. *Am J Physiol Heart Circ Physiol* 2010;298:H795–H806.
- 33 Imig JD, Carpenter MA, Shaw S: The soluble epoxide hydrolase inhibitor AR9281 decreases blood pressure, ameliorates renal injury and improves vascular function in hypertension. *Pharmaceuticals* 2009;2:217–227.
- 34 Zhao X, et al: Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. *J Am Soc Nephrol* 2004;15:1244–1253.
- 35 Koerner IP, et al: Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia. *Front Biosci* 2008;13:2833–2841.
- 36 Xu D, et al: Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. *Proc Natl Acad Sci USA* 2006;103:18733–18738.
- 37 Zhang LN, et al: Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. *Arterioscler Thromb Vasc Biol* 2009;29:1265–1270.
- 38 Zhang LN, et al: Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension. *Eur J Pharmacol* 2011;654:68–74.
- 39 Schuck RN, et al: Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. *Atherosclerosis* 2013;227:442–448.
- 40 Sanders WG, et al: Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor. *Am J Physiol Cell Physiol* 2012;303:C278–C290.
- 41 Kelly BS, et al: Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. *Kidney Int* 2002;62:2272–2280.
- 42 Roy-Chaudhury P, et al: Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies. *Blood Purification* 2003;21:99–110.
- 43 Roy-Chaudhury P, et al: Cellular phenotypes in human stenotic lesions from haemodialysis vascular access. *Nephrol Dial Transplant* 2009;24:2786–2791.
- 44 Kuji T, et al: Efficacy of local dipyrindamole therapy in a porcine model of arteriovenous graft stenosis. *Kidney Int* 2006;69:2179–2185.
- 45 Newman JW, et al: Cytochrome p450-dependent lipid metabolism in preovulatory follicles. *Endocrinology* 2004;145:5097–5105.
- 46 Luria A, et al: Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. *J Biol Chem* 2007;282:2891–2898.
- 47 Borhan B, et al: Improved radiolabeled substrates for soluble epoxide hydrolase. *Anal Biochem* 1995;231:188–200.
- 48 Yang J, et al: Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. *Anal Chem* 2009;81:8085–8093.
- 49 Chiamvimonvat N, et al: The soluble epoxide hydrolase as a pharmaceutical target for hypertension. *J Cardiovasc Pharmacol* 2007;50:225–237.
- 50 Morisseau C, et al: Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. *Biochem Pharmacol* 2002;63:1599–1608.
- 51 Li L, et al: PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms. *J Cell Biochem* 2011;112:289–298.
- 52 Owens GK, Vernon SM, Madsen CS: Molecular regulation of smooth muscle cell differentiation. *J Hypertens Suppl* 1996;14:S55–S64.
- 53 Thyberg J: Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. *Histol Histopathol* 1998;13:871–891.
- 54 Thyberg J, et al: Phenotypic modulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. *J Histochem Cytochem* 1997;45:837–846.
- 55 Li L, et al: Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. *Nephrol Dial Transplant* 2007;22:3139–3146.
- 56 Feng W, et al: EETs and CYP2J2 inhibit TNF- α -induced apoptosis in pulmonary artery endothelial cells and TGF- β 1-induced migration in pulmonary artery smooth muscle cells. *Int J Mol Med* 2013;32:685–693.

- 57 Davis BB, et al: Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. *Proc Natl Acad Sci USA* 2002;99:2222–2227.
- 58 Davis BB, et al: Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. *J Pharmacol Exp Ther* 2006;316:815–821.
- 59 Ng VY, et al: Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. *Arterioscler Thromb Vasc Biol* 2006;26:2462–2468.
- 60 Itoh T, et al: Structural basis for the activation of PPARgamma by oxidized fatty acids. *Nat Struct Mol Biol* 2008;15:924–931.
- 61 Nagy L, et al: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. *Cell* 1998;93:229–240.
- 62 Ozawa T, et al: Biosynthesis of leukotoxin, 9,10-epoxy-12 octadecenoate, by leukocytes in lung lavages of rat after exposure to hyperoxia. *Biochem Biophys Res Commun* 1986;134:1071–1078.
- 63 Marx N, et al: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. *Circ Res* 1998;83:1097–1103.
- 64 Hsueh WA, Jackson S, Law RE: Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. *Diabetes Care* 2001;24:392–397.
- 65 Ricote M, et al: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature* 1998;391:79–82.
- 66 Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. *Nature* 1998;391:82–86.
- 67 Michiels C, et al: Hypoxia stimulates human endothelial cells to release smooth muscle cell mitogens: role of prostaglandins and bFGF. *Exp Cell Res* 1994;213:43–54.
- 68 Laniado-Schwartzman M, et al: Activation of nuclear factor kappa B and oncogene expression by 12(R)-hydroxyeicosatrienoic acid, an angiogenic factor in microvessel endothelial cells. *J Biol Chem* 1994;269:24321–24327.
- 69 O'Flaherty JT, et al: Neutrophil-aggregating activity of monohydroxyeicosatetraenoic acids. *Am J Pathol* 1981;104:55–62.
- 70 Natarajan R, et al: Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. *Proc Natl Acad Sci USA* 1993;90:4947–4951.
- 71 Kawasaki K, et al: Inhibition of 12(S)-hydroxyeicosatetraenoic acid (12-HETE) production suppressed the intimal hyperplasia caused by poor-runoff conditions in the rabbit autologous vein grafts. *J Cardiovasc Pharmacol* 2000;36:555–563.
- 72 Al-Shabraway M, et al: Increased expression and activity of 12-lipoxygenase in oxygen-induced ischemic retinopathy and proliferative diabetic retinopathy: implications in retinal neovascularization. *Diabetes* 2011;60:614–624.